
    
      Study is conducted in 2 parts: part A and part B.

      Part A - Patients with moderate-to-severe AD will be randomized to receive dupilumab (dose 1)
      by auto-injector (AI) device or prefilled syringe.

      Once part A is completely enrolled, part B will randomize patients with moderate-to-severe AD
      to receive dupilumab (dose 2) by auto-injector (AI) device or prefilled syringe.
    
  